Progression of cardiac allograft vascular disease as assessed by serial intravascular ultrasound: correlation to immunological and non-immunological risk factors


Abstract

Objective—To characterise the severity and progression of cardiac allograft vascular disease (CAVD) in a large patient cohort, and to evaluate possible immunological and non-immunological risk factors for progression.

Design—A prospective observational study using intravascular ultrasound.

Setting—Two university hospitals.

Patients and main outcome measures—Changes in focal plaque, lumen, and total vessel area (worst site method) were assessed at baseline and after 12.1 (2.8) months (mean (SD)) of follow up in a cohort of 96 patients (79 male, 17 female; mean age 48.7 (9.6) years; time post-transplant 26.0 (32.4) months).

Results—Overall, the mean (SD) intimal index of worst sites increased by 6.7 (8.8)% per year. The increase in the first 12 months was 7.5 (9.4)% versus 5.9 (8.0)% after the first year (NS). Analysing immunological and non-immunological risk factors (age, underlying disease, sex, donor age, immunosuppression, cytomegalovirus, rejection episodes, cholesterol), low density lipoprotein (LDL) cholesterol was found to be the most important predictor of severe progression (as defined by an increase in intimal index of ≥ 15% (p = 0.01).

Conclusions—Progression of CAVD is characterised by a continuing increase in intimal hyperplasia, especially within the first year after heart transplantation. LDL cholesterol is an important predictor of major progression.

(Heart 2000;84:494–498)

Keywords: heart transplantation; cardiac allograft vasculopathy; intravascular ultrasound

Endothelial dysfunction and multifocal myointimal hyperplasia are major characteristics of cardiac allograft vascular disease (CAVD). Several non-invasive and invasive approaches have been used to characterise this accelerated coronary syndrome. However, intravascular ultrasound has proved to be the most sensitive technique for evaluating the severity and progression of vascular disease in transplanted hearts. In addition to angiographic information, not only luminal dimensions but all major vascular structures, as lumen, plaque, and total vessel area, can be assessed and quantified by intravascular ultrasound. Recent large scale cross sectional studies have provided important insights into the prevalence and distribution pattern of intimal hyperplasia, both early and late after transplantation. However, in the individual patient it is necessary not only to determine whether or not disease is present but also the rate at which disease is progressing. Few studies have focused on this important issue so far. Moreover, beyond descriptive aspects, the question of potential risk factors, identifying patients with a rapid progressive course, is of major clinical interest.

Different approaches have been suggested to quantify the severity of disease. One of these—the "worst site" method—is based on selection of the most diseased vascular sites (defined as the maximal focal intimal index) per vessel segment. The clinical relevance of this approach was confirmed by Mehra et al and Rickenbacher et al and more recently by Klauss et al, who showed that the severity of these lesions was of prognostic relevance. Focusing on a more diffuse manifestation of intimal hyperplasia, averaging procedures using either multiple randomly selected sites or a volumetric approach have been applied. Although these may be more suitable for quantifying the total plaque burden, the clinical relevance of these methods has not been demonstrated so far.

Our aim in this serial intravascular ultrasound study was: first, to characterise the pattern of progression of allograft vasculopathy in the most diseased sites in each vessel; second, to compare progression defined by intravascular ultrasound and by angiography; and third, to analyse possible donor, recipient, and graft related risk factors predicting a rapidly progressive course.

Using identical investigation protocols, this study was performed in two centres, allowing us to analyse data from 96 heart transplant recipients, each of whom had at least two intravascular ultrasound studies over a 12 month period.

Methods

PATIENTS

After obtaining written informed consent, 96 consecutive heart transplant recipients (centre 1 (Hannover) 46; centre 2 (Munich) 50; 79
**p < 0.005; ***p < 0.001; NS, not significant.

### Table 2 Progression of allograft vascular disease over time

<table>
<thead>
<tr>
<th>Change in</th>
<th>Overall (n=96)</th>
<th>≤ 1 year (n=51)</th>
<th>&gt; 1 year (n=45)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plaque area (mm²)</td>
<td>1.3 (1.7)</td>
<td>1.3 (1.9)</td>
<td>1.3 (1.4)</td>
<td>0.87</td>
</tr>
<tr>
<td>Lumen area (mm²)</td>
<td>-0.4 (2.0)</td>
<td>-1.1 (2.8)</td>
<td>0.4 (2.1)</td>
<td>0.003</td>
</tr>
<tr>
<td>Vessel area (mm²)</td>
<td>0.9 (3.0)</td>
<td>0.2 (3.1)</td>
<td>1.7 (2.7)</td>
<td>0.009</td>
</tr>
<tr>
<td>Intima index (%)</td>
<td>6.7 (8.8)</td>
<td>7.5 (9.4)</td>
<td>5.9 (8.0)</td>
<td>0.35</td>
</tr>
</tbody>
</table>

**p < 0.005; ***p < 0.001; NS, not significant.

#### CAVD was graded using a standardised scale. To allow for comparison with data from intravascular ultrasound examinations, only vessels that were also assessed by intravascular ultrasound were used for grading. Progression of disease was defined as an increase of at least one step in scale.

### ULTRASOUND ANALYSIS

Image analysis was performed off-line from the videotape using a conventional image analysis system (Tape Measure, Indec Systems, San Francisco, California, USA). After reviewing the complete imaging sequence, the analysed part of each vessel was divided into three segments: proximal, mid-vascular, and distal. The vascular site within each third of the vessel that had the highest intimal index was chosen for further analysis (worst site approach). “Lumen” was defined as the area within the intimal border, “total vessel” as the area within the media/adventitia boundary (characterised by the external border of the echolucent zone), and “plaque” as the space between vessel area and lumen area. Intimal index was calculated as plaque area divided by vessel area multiplied by 100. The mean plaque area, mean vessel area, mean lumen area, and mean intimal index per patient were defined as mean values of all segments analysed. Identical protocols were applied at baseline and at the follow up examination. Our primary intention was to identify worst sites in each vessel segment; in many cases but not all, these reflected identical vascular sites. An increase in intimal index of more than 15% as compared with the baseline examination was regarded as representing severe progression.

### STATISTICAL ANALYSIS

Statistical analysis was performed using a computer assisted software package (SPSS, version 6.1.3). Continuous data are presented as mean (SD). A probability value p < 0.05 was considered significant.

The Student t test was used to compare for differences in intimal index, plaque, lumen, and vessel area within the first year (“early period”) and beyond the first year (“late period”) after transplantation.

Bivariate assessment for statistical differences in immunological and non-immunological risk factors between patients with and without severe progression was done using the χ² test (non-continuous variables) and the t test (continuous variables). In addition a multivariate analysis was performed by logistic regression (backward, LR).
Results
Serial intravascular ultrasound studies were performed in 159 vessels, 1.7 (0.5) vessels/patient. Two vessels (left anterior descending and circumflex) were examined in 63 patients and one vessel in 33 (left anterior descending in 29; circumflex in four). In all, 475 vascular sites (4.9 (1.4) sites per patient) were evaluated.

PLAQUE AREA
A uniform and significant increase by 1.3 mm (p < 0.001) was observed in the total patient cohort as well as in the subgroups < 1 year and > 1 year after transplantation (tables 1 and 2).

LUMEN AREA
Luminal area did not change significantly between baseline and follow up examination in the cohort as a whole. However, when the patients were broken down by time after transplantation, within the first year after their transplant there was a decrease in mean lumen area (-1.1 (2.8) mm), while after the first year there was a small but significant increase in lumen area (+0.4 (2.1) mm; p = 0.003) (tables 1 and 2).

VESSEL AREA
During follow up an overall increase in total vessel area was observed in all patients (from 13.6 (4.1) mm to 14.5 (4.2) mm, p < 0.005) (table 1). Analysing the subgroups early and late after transplantation, the increase in vessel area was mainly a late feature, with an increase of 1.7 (2.7) mm after the first year compared with 0.2 (3.1) mm within the first 12 months (p < 0.009) (table 2).

INTIMAL INDEX
A constant and significant increase in mean intimal index was observed throughout the entire observation period. There were no statistical differences between the early and late periods.

RISK FACTOR ANALYSIS
To identify a subgroup with severe progression of disease, we chose for further risk factor analysis patients with an increase in intimal index of > 15% (n = 16, 16.6% of the total patient cohort, 11 of 51 patients within the first year, five of 45 patients beyond the first year). Comparing this subgroup with patients with a smaller increase in intimal index (≤ 5%), we assessed several immunological and non-immunological risk factors (age, underlying disease, sex, donor age, type of immunosuppression, cytomegalovirus infection, rejection episodes, cholesterol, high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol). Both bivariate and multivariable analysis (logistic regression) identified LDL cholesterol (p = 0.01) as the only factor associated with severe progression (table 3).

ANGIOGRAPHIC PROGRESSION
Using a semiquantitative score (grade 0 to grade 4, table 4), angiography revealed progression of disease by at least one grade in 22 patients (10 of 51 within the first year and 12 of 45 beyond the first year after transplantation). However, only 14 of 49 patients with an increase in intimal index of ≥ 5%, six of 28 with an increase of ≥ 10%, and three of 16

Table 3 Risk factors for progression of intimal index (≥ 15% v < 5%)

<table>
<thead>
<tr>
<th></th>
<th>Overall (n=96)</th>
<th>Progression &lt; 5% (n=46)</th>
<th>Progression ≥ 15% (n=16)</th>
<th>p Value (bivariate)</th>
<th>p Value (multivariate)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age years</td>
<td>48.7</td>
<td>49.4 (8.2)</td>
<td>50.0 (9.4)</td>
<td>0.82</td>
<td>0.25</td>
</tr>
<tr>
<td>Underlying disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CAD/other</td>
<td>34/62</td>
<td>19/27</td>
<td>6/10</td>
<td>0.62</td>
<td>0.3</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>male/female</td>
<td>79/17</td>
<td>36/10</td>
<td>14/2</td>
<td>0.44</td>
<td>0.17</td>
</tr>
<tr>
<td>Donor age years</td>
<td>33.6 (11.9)</td>
<td>33.4 (12.9)</td>
<td>30.5 (11.1)</td>
<td>0.40</td>
<td>0.57</td>
</tr>
<tr>
<td>Immunosuppression</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CyA/Tac</td>
<td>81/15</td>
<td>40/6</td>
<td>13/3</td>
<td>0.72</td>
<td>0.81</td>
</tr>
<tr>
<td>CMV disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>pos/neg</td>
<td>0.15 (0.51)</td>
<td>0.15 (0.47)</td>
<td>0.25 (0.78)</td>
<td>0.63</td>
<td>0.49</td>
</tr>
<tr>
<td>Rejection episodes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>number</td>
<td>1.3 (1.7)</td>
<td>1.1 (1.5)</td>
<td>1.3 (1.4)</td>
<td>0.82</td>
<td>0.23</td>
</tr>
<tr>
<td>Cholesterol mmol/l</td>
<td>6.27 (1.17)</td>
<td>6.08 (1.42)</td>
<td>6.66 (1.42)</td>
<td>0.17</td>
<td>0.89</td>
</tr>
<tr>
<td>HDL cholesterol mmol/l</td>
<td>1.39 (0.48)</td>
<td>1.42 (0.45)</td>
<td>1.28 (0.42)</td>
<td>0.29</td>
<td>0.17</td>
</tr>
<tr>
<td>LDL cholesterol mmol/l</td>
<td>3.94 (1.26)</td>
<td>3.71 (1.29)</td>
<td>4.57 (0.99)</td>
<td>0.01</td>
<td>0.02</td>
</tr>
</tbody>
</table>

CAD, coronary artery disease; CMV, cytomegalovirus; CyA, cyclosporin A; Tac, tacrolimus; HDL, high density lipoprotein; LDL, low density lipoprotein.

Table 4 Angiographic progression of disease

<table>
<thead>
<tr>
<th></th>
<th>Total</th>
<th>Angio grade 0</th>
<th>Angio grade 1</th>
<th>Angio grade 2</th>
<th>Angio grade 3</th>
<th>Angio grade 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline study (n (%))</td>
<td>96</td>
<td>69 (71.9%)</td>
<td>11 (11.5%)</td>
<td>8 (8.3%)</td>
<td>6 (6.3%)</td>
<td>2 (2.1%)</td>
</tr>
<tr>
<td>Follow up study (n (%))</td>
<td>96</td>
<td>59 (61.5%)</td>
<td>13 (13.5%)</td>
<td>8 (8.3%)</td>
<td>13 (13.5%)</td>
<td>3 (3.1%)</td>
</tr>
</tbody>
</table>

Grade 0, normal angiogram; grade 1, wall irregularities with luminal obstruction < 30%; grade 2, luminal obstruction 30–50%; grade 3, luminal obstruction ≥ 50%; grade 4, vessel occlusion.
Assessment of cardiac allograft vascular disease

with an increase of ≥15% were identified by coronary angiographic progression (fig 1).

Discussion
Since the introduction of intravascular ultrasound into clinical practice, several cross sectional studies have been performed to define the severity and distribution pattern of cardiac allograft vascular disease. However, little is known about the characteristics of progression—in our opinion essential information not only in relation to its scientific aspects but also for the clinical management of the patients. Using intravascular ultrasound, our aim in this study was to define the natural course of progression, to identify recipients at risk, and to assess possible risk factors predicting a rapidly progressive course.

Overall, CAVD was confirmed to be an accelerated coronary syndrome. Using the worst site approach, mean intimal index could be shown to increase by 6.7 (8.8)% in 12 months, and the increase was particularly pronounced within the first year after transplantation (7.5 (9.4)%, compared with 5.9 (8.0)% after the first year). Bivariate and multivariate analysis showed that LDL cholesterol was the most important and only significant risk indicator for severe progression, defined as an increase in the intimal index ≥15%.

PROGRESSION OF DISEASE: ANGIOGRAPHY OR INTRAVASCULAR ULTRASOUND
Intravascular ultrasound can be regarded as the optimal imaging procedure for characterising intimal hyperplasia and luminal loss in CAVD, while angiographic methods have been shown to be insensitive. This was confirmed in the present study. Less than 30% of patients found to have an increasing intimal index on intravascular ultrasound examination had detectable changes in their coronary angiography. This supports the important role of intravascular ultrasound as a diagnostic tool in any therapeutic approach.

To define the natural course of progression, we considered the following issues to be of special interest. First, when does progression occur? Second, what is the mean progression rate over time? And third, what are the vascular structures involved in progression?

Histopathological studies and data from a multicentre intravascular ultrasound trial have shown that the largest increase in intimal index occurs within the first year after heart transplantation. Those results were confirmed by our present study. However, long term angiographic follow up has shown that progression of disease continues after the first year. Thus at a mean (SD) of 4.6 (2.3) years after transplantation, there was only a slightly pronounced within the first year after transplantation (7.5 (9.4)%, compared with 5.9 (8.0)% after the first year). Bivariate and multivariate analysis showed that LDL cholesterol was the most important and only significant risk indicator for severe progression, defined as an increase in the intimal index ≥15%.

RISK FACTORS
In view of the likely presence of remodelling processes, we chose the intimal index as a combined measure, representing plaque as well as vessel area, to characterise progression. Our analysis shows that progression of CAVD is highly variable between individuals. While the majority of patients presented with a moderate increase in intimal index, 16 were found to have severe progression (≥15% increase in intimal index). Assuming that these differences in progression may be influenced by patient, graft, or environment related factors, we analysed multiple immunological and non-immunological variables in patients presenting with severe progression (11 within the first year and five beyond the first year after transplantation). Using both bivariate and multivariate analysis, LDL cholesterol (4.57 (0.99) mmol/l ≥ 3.71 (1.29) mmol/l) was found to be significantly increased in the progression group. These findings correspond to previously published results from cross sectional and interventional studies, showing raised cholesterol concentrations to be one of the most important factors associated with abnormal intimal thickening. Intracellular and extracellular lipid deposition and the induction of myointimal hyperplasia are thought to be the most probable mechanisms in pathogenesis. These results suggest that effective lipid lowering treatment should be offered to these patients, especially those with progressive intimal hyperplasia.

In contrast to previous findings, other immunological and non-immunological risk factors (such as rejection episodes, immunosuppression, cytomegalovirus infection, donor age, and sex) were not found to correlate with severe progression of disease in the present study. Because of the comparatively short observation period, our current data do not rule out the possibility that these factors may play a part. However, they would appear to be of minor importance in the setting analysed here.
LIMITATIONS
As discussed above, progression of CAVD is a complex and continuing process. This study represents a first approach to characterising its progression in a large patient cohort. A definite limitation is the follow up period of only 12 months, which precludes any speculation about longer periods of observation. A second limitation is that the analysis focused on the worst sites of each vessel segment in identifying the maximum severity of disease. However, in view of the possible remodelling process, this procedure may not be optimal. Further studies with plaque volumetry in defined segments may improve the comparability of the measurements. Finally, in order to collect an acceptable sample size, this study was carried out in two centres. Although the therapeutic and diagnostic protocols were nearly identical and the patient characteristics and the pattern of progression did not differ significantly between the two centres, minor differences in management cannot be ruled out.

CONCLUSIONS
Serial intravascular ultrasound examinations showed that progression of cardiac allograft vasculopathy was characterised by a continuing increase in intimal hyperplasia, which was most pronounced within the first year after heart transplantation. Using the worst site approach, the degree of luminal narrowing was shown to be influenced not only by an increase in plaque area but also by coronary artery remodelling processes. There was a large degree of interindividual variability in progression. LDL cholesterol was shown to be an important predictor of severe progression.